-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectar enrolls first patient in Phase 1b CLR 125 trial for TNBC

PUBT·04/14/2026 12:36:32
Listen to the news
Cellectar enrolls first patient in Phase 1b CLR 125 trial for TNBC
  • Cellectar Biosciences enrolled first patient in Phase 1b trial of CLR 125, an iodine-125 radioconjugate, in relapsed or refractory triple negative breast cancer.
  • Trial will assess safety, tolerability, tumor targeting, and early signs of anti-tumor activity, with no clinical results presented yet.
  • Management plans to report dosimetry, safety, and efficacy updates throughout 2026.
  • Program builds on clinical experience with iopofosine I-131, while positioning CLR 125 as a differentiated candidate with a distinct therapeutic profile.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140835PRIMZONEFULLFEED9689011) on April 14, 2026, and is solely responsible for the information contained therein.